I don't think the name has changed in the past year. The stock probably dropped because in an effort to raise money they issue notes at such a low value that those new investors or whoever they are can sell at the current price while old holders lose their tail. Would guess it keeps new capital raising to that select group an advantage to the CEO and detriment of share holders. There is really no other explanation for the fall. They had some qc issues that should have been easy to remedy with implementation of process controls and documentation. The kinds of things any company with FDA oversite has to do. Would have hoped the CEO had a plan for all that rather then wait for a negative report to address it. This company could definitely be better at reporting its current situation. The management is responsible for the share value as a reflection of how it has carried out a business plan. I would give it an F grade as of late. On the plus side it could bounce back if they wanted it too.